CMML CPSS-Mol
Estimate risk of progression to AML in those with CMML using molecular genetics data
Author / Source: Matthew Cheung, MD, FRCP(C)
The CPSS-Mol is a new CMML-specific prognostic scoring system (CPSS) that incorporates molecular genetic data resulting in a 4-level integrated clinical/pathological/genetic risk stratification tool. This tool was derived from a cohort of European patients, 93% of whom possessed 1 of 38 somatic mutations. Based on multivariable Cox regression analyses, cytogenetic abnormalities and mutations in RUNX1, NRAS, SETBP1, and ASXL1 were independently associated with overall survival (OS). The CPSS-Mol fully retained its ability to risk stratify survival in an independent validation cohort of CMML patients.
- [1]Elena C, Galli A, Such E, et al.: Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood 2016;128(10):1408-1417
Results
Real-time automated computation
The CPSS-Mol is a new CMML-specific prognostic scoring system (CPSS) that incorporates molecular genetic data resulting in a 4-level integrated clinical/pathological/genetic risk stratification tool. This tool was derived from a cohort of European patients, 93% of whom possessed 1 of 38 somatic mutations. Based on multivariable Cox regression analyses, cytogenetic abnormalities and mutations in RUNX1, NRAS, SETBP1, and ASXL1 were independently associated with overall survival (OS). The CPSS-Mol fully retained its ability to risk stratify survival in an independent validation cohort of CMML patients.
- [1]Elena C, Galli A, Such E, et al.: Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood 2016;128(10):1408-1417